DDIT3 and mature T-cell and NK-cell non-Hodgkin lymphoma: On the other hand, ICED showed a trend toward better PFS in PTCL-NOS patients, although this was not statistically significant (Figure 4C), and ICED was favored over CHOP in EATL/HSTL patients, although the number of patients was small (Figure 4A).